More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura.
Sign Up to like & getrecommendations! Published in 2022 at "Blood advances"
DOI: 10.1182/bloodadvances.2022009021
Abstract: : Conflict of interest: COI declared - see note COI notes: Y.B. is a member of the French advisory boards for Sanofi and Takeda. A.V. is a member of the French advisory boards for Sanofi,… read more here.
Keywords: frontline caplacizumab; mediated thrombotic; immune mediated; caplacizumab immune ... See more keywords